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Abstract
Introduction The management of drug–drug interactions
(DDIs) is a complex process in which risk–benefit assess-
ments should be combined with the patient’s perspective.
Objective The aim of this study was to determine patients’
and pharmacists’ preferences regarding DDI management.
Methods We conducted a choice-based conjoint survey
about a fictitious DDI concerning the combination of a
cardiovascular drug and an antibiotic for pneumonia.
Patients and pharmacists had to choose 12 times between
two management options. The options were described by
five attributes, including risk, benefit and practical conse-
quences. Each attribute could have two different levels,
which were varied over the choice tasks. Latent class
analysis was used to identify potential classes of respon-
dents with distinct patterns of similar preferences.
Results In total, 298 patients and 178 pharmacists com-
pleted the questionnaire. The latent class model for both
patients and pharmacists resulted in three classes. For
patients, in one class the most importance was attached to
avoiding switch of medication (class probability 20%), in a
second class to fewer adverse events (41%), and in a third
class to blood sampling (39%). For pharmacists, again one
class attached the highest importance to avoiding switch of
medication (31%). The other classes gave priority to curing
pneumonia (31%) and avoiding blood sampling (38%).
Conclusion The results showed diverging preferences
regarding DDI management among both patients and
pharmacists. Different groups attached different value to
risk and benefit versus practical considerations. Awareness
of existing variability in preferences among and between
pharmacists and patients is a step towards shared decision
making in DDI management.
Key Points
Risk–benefit assessments for drug–drug interaction
management should incorporate the patient’s
perspective.
Both patients and pharmacists have diverging
preferences regarding drug–drug interaction
management.
The development and application of drug interaction
management recommendations can benefit from the
awareness of existing variability of preferences.
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article (doi:10.1007/s40264-017-0601-7) contains supplementary
material, which is available to authorized users.
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1 Introduction
Clinical risk management of drug–drug interactions (DDIs)
is complex. The management recommendations for DDIs
often provide healthcare professionals with several options
(e.g. additional monitoring, switch to an alternative drug,
dose adjustment). These recommendations are generally
based on the principle of evidence-based medicine and are
dominated by risk–benefit assessments [1, 2]. In DDI
management, these assessments are difficult because at
least two drug therapies are involved and because the
evidence for the different management options is generally
limited. Moreover, recognizing the importance of shared
decision making, the patient’s perspective should be
included [3–5]. In shared decision making, patients and
healthcare professionals make healthcare decisions toge-
ther, taking into account both scientific evidence and the
patient’s values and preferences [6].
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach offers an evi-
dence-to-decision framework for clinical decisions [7, 8].
The aspects involved in DDI decision making and clinical
decision making in general are similar, with a complex
risk–benefit balance of the therapeutic options being cen-
tral in the assessment, and with uncertainty being high.
Therefore, the GRADE approach has also been proposed—
and used—for the assessment of DDI management [1, 9].
The GRADE model includes, in addition to aspects such as
risk and benefit, variability in how patients value the main
outcome. The acceptability and the feasibility of a rec-
ommendation for patients and healthcare providers are also
part of the model. Thus, it is recognized that patients’
values and preferences and their variability are relevant in
the development of DDI management recommendations.
In addition to the role of patients’ preferences in the
development of recommendations, the patients’ perspective
should be taken into account in the application of recom-
mendations in daily practice [5, 10]. Currently, DDI man-
agement by pharmacists and physicians usually does not
explicitly involve the patient’s perspective. Little is known
about patients’ preferences in the field of DDI management
and about potential incongruence with professionals’ pref-
erences. Based on investigations of patient preferences in
other drug-related issues, variability among patients could
be expected [11–13]. Both patients’ and healthcare provi-
ders’ perspectives may influence the choice of a specific
DDI management option. Insight into these perspectives is
useful for shared decision making in this field. The
responsibility for DDI management is shared between the
physician and the pharmacist but is a main focus for phar-
macists. Therefore, we aimed to investigate patients’ and
pharmacists’ preferences with regard to DDI management.
2 Methods
2.1 Study Design
A structured online questionnaire was administered to
patients and community pharmacists. The core task was a
choice-based conjoint (CBC) task on a fictitious DDI
regarding a patient using cardiovascular medication who
was in need of an antibiotic because of suspected pneumo-
nia. In the CBC, respondents had to choose between hypo-
thetical options to determine the characteristics of an option
to which they attached value (see Sect. 2.3). The CBC task
was essentially the same for pharmacists and patients.
Patients were asked to choose for themselves; pharmacists
were asked to choose for a patient in general. The complete
pharmacist questionnaire comprised sociodemographic
characteristics, the CBC task, and an open question on sit-
uations or patient groups in which the preferences of the
pharmacist would differ from the choices made in the CBC.
The complete patient questionnaire comprised four parts:
general questions on sociodemographic characteristics and
drug use, the CBC task, a questionnaire on numeracy and a
questionnaire on health literacy.
2.2 Participants and Protocol
Pharmacists were recruited from the Utrecht Pharmacy
Practice Network for Education and Research (UPPER),
which includes two-thirds of the 1900 Dutch community
pharmacies [14]. The usual response rate in this network is
10–15%. Email invitations included the URL of the online
questionnaire, and a reminder was sent after 1–2 weeks.
Patients were recruited via a convenience sample of five
community pharmacies from different regions in the
Netherlands. Patients who were using cardiovascular drugs
were selected to ensure that the fictitious DDI presented
would be plausible. The patient selection was made from
the pharmacy information system, which contains elec-
tronic patient records including a medication dispensing
history and a coded registration of chronic conditions. A
sample of 200 patients per pharmacy was randomly
selected out of the patients who met the following inclusion
criteria:
1. Aged[ 40 years
2. Use of cardiovascular medication based on dispensing
data. We considered the following cardiovascular
medication (anatomical therapeutic chemical [ATC]
class [15]): lipid-modifying agents (C10), platelet-
aggregation inhibitors (B01AC) and antihypertensive
drugs (C03 diuretics, C07 beta-blocking agents, C08
calcium channel blockers or C09 renin angiotensin
system inhibitors)
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3. Registered indication for cardiovascular risk manage-
ment: hypertension, heart failure, coronary disease,
diabetes mellitus or stroke
4. Available email address
5. No known terminal illness or impaired cognition
Patients were invited via email by their own pharmacist,
with a reminder after 1–2 weeks.
2.3 Choice-Based Conjoint Task
Conjoint analyses and discrete-choice experiments, such as
CBC, are increasingly used in healthcare to elicit and
quantify respondents’ preferences [16, 17]. In CBC,
respondents choose between hypothetical options that
systematically vary in the value (level) of selected attri-
butes, which reflects issues relevant to the decision. A CBC
task was developed in accordance with guidelines [18–20],
using Sawtooth Software (Lighthouse Studio version 9.2.0,
Orem, UT, USA). The CBC was based on a fictive case
illustrative of DDIs (Fig. 1), and plausible for a broad
group of respondents: cardiovascular medications are
among the most frequently used drugs and they often cause
DDIs [21]. In the first step of the development of the CBC
task, realistic attributes and levels were preselected
(Table 1), representing four common DDI management
options that could be applied after consultation between
prescriber, pharmacist and patient: (1) no action, use both
drugs concurrently; (2) replacement of the medicine the
patient is already using; (3) replacement of the newly
prescribed medicine; (4) additional monitoring such as
blood testing [1]. The case, attributes and levels were
selected based on considerations relevant in the develop-
ment of drug interaction management guidelines [1, 8, 9]
and the content of DDI management guidelines [22, 23].
This preselection was carried out by the research group,
comprising four pharmacists experienced in pharmacy
practice research and DDI assessment (one being a prac-
tising community pharmacist) and one psychologist. Sec-
ond, the preselection of attributes was verified in five focus
group meetings with a total of 38 patients using cardio-
vascular drugs, which were part of a parallel running
investigation (manuscript in preparation). The focus groups
were held in five community pharmacies and based on a
DDI case very similar to the example in the CBC task.
Patients were asked for their preferences in DDI manage-
ment and the underlying rationale. Focus groups were
audiotaped, transcribed, and analysed using inductive
analysis of themes. The rationales expressed by the patients
were assessed for potentially relevant attributes for the
CBC task. Based on the focus groups, no new attributes
were added, but a cost attribute was excluded. In the
Netherlands, this attribute is not relevant for patients with
chronic conditions because costs are covered by insurance,
and therefore the cost component was experienced as
unrealistic and confusing by the patients participating in
the focus groups.
In the third step, the questionnaire was pre-tested by
patients and pharmacists for understanding, feasibility and
Fig. 1 Annotated example of choice set for patients. Example of a
choice set, starting with a short description of the case (wording for
patients). The choice set shows two options; respondents have to
choose either option A or option B. For the complete questionnaire,
see Electronic Supplementary Material 1
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wording. A number of 12 choice sets was chosen to limit
the time needed to complete the questionnaire to 10 min
for pharmacists and to 15 min for patients (the patient
questionnaire took longer because of the additional parts
about health literacy and numeracy). The questionnaire was
adapted according to the feedback in a cyclic process (two
respondents per target group per cycle), until after three
cycles no new issues were identified and good under-
standing was reached.
In the final questionnaire, the participating patients and
pharmacists had to respond to 12 choice sets with two DDI
management options each. Because of the complexity of
the subject, the number of options was limited to two per
choice set; no opt-out option was available, consistent with
reality. The options to choose from were characterised by a
full profile of five attributes. The attributes were presented
in the same order for any given respondent, but the order
was randomised between respondents. A balanced overlap
design (with level balance and near orthogonality) was
used to create the choice sets [18, 24]. We generated 20
different combinations of 12 choice sets, which were ran-
domly assigned to the respondents. The CBC was preceded
by an explanation of the case and the choice task; a pop-up
with additional information on the attributes and levels was
available during the CBC. For a translated example of a
choice set, see Fig. 1; for the complete CBC task, see
Electronic Supplementary Material (ESM) 1.
2.4 Health Literacy and Numeracy Measurement
Measures of health literacy and numeracy were included to
detect potential associations with preferences, as literacy
and numeracy can influence decision making [25–29]. The
Dutch versions of the validated Functional Communicative
and Critical Health Literacy Scales (FCCHL) and the
Subjective Numeracy Scale (SNS) were used.
The FCCHL comprises 14 statements about handling
health information [30, 31]. The items are divided over
three subscales: functional health literacy (understanding
health information, five items), communicative health lit-
eracy (finding and using health information, five items) and
critical health literacy (assessing health information, four
items). Each item is rated on a 4-point scale, ranging from
1 (never/easy) to 4 (often/hard). After reversion of all
scores, the scores on the items in a (sub)scale were summed
and divided by the number of items in the scale to calculate
a scale score (theoretical range 1–4, with a higher score
indicating higher health literacy).
The SNS comprises eight statements about respondents’
performance and preferences with regard to handling
numeric information in daily life. All items are rated on a
6-point scale, ranging from 1 (not at all good/never) to 6
(extremely good/very often) [27, 28, 32]. After reversion of
item 7, the total score was calculated by summing the item
scores and dividing them by eight. The theoretical range is
Table 1 Attributes and levels












Blood sampling twice during
antibiotic course
Whether or not blood is sampled twice during the antibiotic course.
By blood testing, muscle problems can be diagnosed at an early
stage, before they become serious




The chance of recovering from pneumonia without hospitalization In 95 of 100
people
MO1, MO2, MO4
In 90 of 100
people
MO3
Moderate muscle pain The risk of moderate muscle pain. With moderate muscle pain, you
are limited in your daily activities (work, hobby)
In 5 of 100
people
MO2, MO3





Whether or not you switch to another cardiovascular medicine, instead
of the one you are using at the moment
No MO1, MO3, MO4
Yes MO2
DDI drug–drug interaction, MO management option
a MO1: no action, use both drugs concurrently; MO2: replacement of the medicine the patient is already using; MO3: replacement of the newly
prescribed medicine of choice; or MO4: extra monitoring by blood testing
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1–6, with a higher score indicating higher numeracy. For
the complete FCCHL and SNS, see ESM 1.
2.5 Sample Size
Because of the exploratory nature of this study and the
potential variability, an a priori estimation of effect size
was not available. Taking into account general guidelines
for CBC, the targeted sample size was 200 patient
respondents and 200 pharmacist respondents [18, 19]. The
aim of our study was to obtain a general overview of
preferences and potential variability in DDI management
based on a fictitious case rather than an exact estimate of
choice behaviour in DDI management.
2.6 Data Analysis
We used Microsoft Excel 2010 and SPSS version 20.0
(SPSS Inc., Chicago, IL, USA) for descriptive statistics of
basic characteristics. For non-responders analysis for
patients, differences between groups were analysed using
the t test for normally distributed continuous variables and
Pearson’s Chi squared test for categorical variables. P-
values\ 0.05 were considered statistically significant.
Only completed questionnaires were included in further
analysis.
The CBC data were analysed using Sawtooth Software.
CBC analysis results in utilities, which are similar to a
regression coefficient and represent the relative attractive-
ness (preference) of an attribute level and therefore its
relative influence on the respondents’ choice. Positive
utilities reflect the preferred level; higher values reflect
greater attractiveness. The importance of an attribute [rel-
ative importance (RI)], i.e. how much it contributes to the
respondents’ choice, is calculated by dividing the absolute
value of the utility by the sum of the absolute value of all
utilities.
We analysed the CBC data using latent class analysis
[33] to examine the presence of classes (subgroups) of
respondents with different preferences. In latent class
analysis, the classes are ‘latent’: they are derived from
distinct patterns of similar preferences in the data. Suc-
cessive latent class models were estimated for one to five
classes. The most likely number of classes was evaluated
by assessing the goodness-of-fit indices for the model.
Various goodness-of-fit statistics are available for latent
class analysis, which we inspected in conjunction with each
other. We assessed the LogLikelihood, McFadden’s pseudo
q2 (value between 0.2 and 0.4 indicates good fit), Akaike
information criterion (AIC; lower values indicate better fit)
and Bayesian information criterion (BIC; lower values
indicate better fit) [20, 33]. In addition, the pattern of
utilities for every model was assessed. Moreover, mean
class probabilities (the mean of the probability that a
respondent belonged to this class) were taken into account
to maintain clinically relevant class sizes. Based on these
considerations, the most likely number of classes (optimal
model) was established for both patients and pharmacists.
Subsequently, we tested whether every attribute signifi-
cantly contributed to the model by a Chi squared test on the
-2LogLikelihood based on the difference between the
model with and without every single attribute.
For the final model, every respondent was assigned to
the class for which she/he had the highest probability, and a
comparison between classes was made with respect to the
respondents’ basic characteristics in SPSS. Analysis of
variance (ANOVA) was used for normally distributed
continuous variables and Pearson’s Chi squared test for




An invitation was sent to 1312 pharmacists between
September and December 2016. The questionnaire was
accessed by 236 (18.0%) and completed by 178 (13.5%)
pharmacists. See Fig. 2 for a flowchart of this process and
Table 2 for respondents’ basic characteristics.
Five pharmacists selected 200 eligible patients each;
invitations were emailed to 1000 patients between
September and December 2016. The online questionnaire
was accessed by 393 (39.3%) and completed by 298
(29.8%) patients. Between patients who completed the
questionnaire (n = 298) and patients who filled out the
basic characteristics but did not complete the questionnaire
(n = 79), there were differences with respect to age (mean
age 64.4 vs. 67.9 years; p = 0.01) and educational level
[low 26.9% (n = 79) vs. 48.0% (n = 36); medium 39.1%
(n = 115) vs. 33.3% (n = 25); high 34.0% (n = 100) vs.
18.7% (n = 14); p\ 0.01]. No differences were seen with
respect to sex, duration of use of cardiovascular drugs and
number of medicines in use.
3.2 Latent Class Analysis
The latent class analysis for both patients and pharmacists
resulted in a three-class model. McFadden’s pseudo q2 was
0.24 for patients and 0.37 for pharmacists. Fit statistics
indicated improvement in model fit with each additional
class (see ESM 2) but with decreasing gain in model fit.
With more than three classes, small classes and unclear
differentiation arose compared with the number of
respondents and attributes. The three-class models were
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stable and had an average maximum class membership
probability of 89.0% and 89.8% for patients and pharma-
cists, respectively. All attributes significantly contributed
to the model for both pharmacists and patients.
For patients, level utility and attribute importance are
shown per class in Table 3. In all classes, a lower risk of
muscle damage was preferred over a higher risk, a lower
risk of moderate muscle pain was preferred over a higher
risk, and a higher chance of curing pneumonia was pre-
ferred over a lower chance (reflected by positive utilities
for the preferred level and negative utilities for the non-
preferred level). Preferences were less consistent for blood
Fig. 2 Flowchart respondents
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sampling and switch of cardiovascular drug. In the first
class, the most importance was attached to avoiding a
switch of the cardiovascular drug in use (RI 58.9%), fol-
lowed by minimizing the risk of muscle damage (RI
21.9%). This class was labelled ‘stability focused’. In the
second class, the most value was attached to minimizing
the risk of muscle damage (RI 49.7%) and maximizing the
chance of curing pneumonia without hospitalization (RI
24.3%). This second class was labelled ‘risk focused’. In
the third patient class, labelled ‘certainty focused’, options
with blood sampling were preferred over options without
(RI blood sampling 30.5%). The patients’ descriptive
characteristics shown in Table 2 were not significantly
associated with class assignment (see ESM 3a).
The pharmacists’ results are shown in Table 4. In all
classes, lower risks of harm were preferred over higher
risks, higher chances of cure were preferred over lower
chances, and avoidance of blood sampling and of switch of
current medication was preferred. In the first class, the
highest importance was attached to the risk of muscle
damage (RI 40.6%) and the chance of curing pneumonia
without hospitalization (RI 41.4%). This first pharmacist
class was labelled ‘risk focused’. In the second class,
maintaining the current cardiovascular medication was
valued most (RI 61.2%); this class was labelled ‘stability
focused’. In the third class, priority was given to avoidance
of blood sampling (RI 38.8%), followed by avoidance of
the switch of current cardiovascular medication (RI
25.2%) and a low risk of muscle damage (RI 20.0%). This
pharmacist class was labelled ‘practicality focused’. In a
univariate analysis, pharmacist age, sex and years of
practice were all associated with class assignment (re-
spectively, p = 0.01, p = 0.00; p = 0.02); see ESM 3b.
The ‘risk focused’ pharmacists were the oldest, had been
in practice for the most years, and were more often male.
The ‘stability focused’ pharmacists were the youngest, had
been in practice for the least years, and were more often
female.
Table 2 Descriptive characteristics of respondents
Patients n = 298
Age Mean (SD) 64.4 (9.6)
Sex Male 186 (62.4%)
Educational levela Low 79 (26.9%)
Medium 115 (39.1%)
High 100 (34.0%)
Number of medicines in use Mean (SD) 4.7 (2.7)
Duration of use of cardiovascular medicines \ = 5 years 27.9%
[ 5 years 72.1%
SNS Mean (SD) 4.2 (0.8)
FCCHL total Mean (SD) 2.9 (0.5)
FCCHL functional Mean (SD) 3.0 (0.5)
FCCHL communicative Mean (SD) 3.2 (0.6)
FCCHL critical Mean (SD) 2.6 (0.7)
Pharmacists n = 178
Age Mean (SD) 43.2 (11.2)
Sex Male 77 (43.3%)
Years of practice in community pharmacy 0–5 36 (20.2%)
6–15 57 (32.0%)
[ 15 85 (47.8%)
Location of pharmacy Village (up to 20,000 inhabitants) 71 (39.9%)
Town (20,000–150,000 inhabitants) 61 (34.3%)
City (over 150,000 inhabitants) 46 (25.8%)
Type of community pharmacy Community health centre 92 (51.7%)
Other 86 (48.3%)
FCCHL Functional Communicative and Critical Health Literacy Scales, SD standard deviation, SNS subjective numeracy scale
a Educational level was categorized as low (primary education or lower secondary), medium (intermediate/higher secondary or intermediate
vocational), or high (higher vocational/university); data were missing for four respondents
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3.3 Pharmacists’ Additional Considerations
Eighty-six pharmacists (48%) reported one or more situa-
tions in which their preferences would differ from those
expressed in the CBC task. Clinical, risk-related situations
(e.g. muscle problems in anamnesis, very serious cardio-
vascular disease) were reported by 64 pharmacists, issues
with respect to the practicality and feasibility of the man-
agement options (e.g. switch of medication is undesirable
for mentally challenged patients; blood testing is undesir-
able for immobile patients) by 16, patient preferences
(unwilling to switch medication, fear of adverse events,
fear of needles) by 14, and prescriber preferences by five.
4 Discussion
Divergent preferences with regard to DDI management
were observed for both patients and pharmacists. Among
both patients and pharmacists, in one class highest
importance was attached to risks and benefits (avoidance of
serious muscle problems, cure of pneumonia). This pattern
of preferences can be characterized as ‘risk focused’ (31.3
and 41.0%). Similarly, among both pharmacists and
patients, in a second class (31.1 and 20.3%) the highest
importance was attached to avoiding changes in the current
therapy (‘stability focused’). For pharmacists, the third
class was ‘practicality focused’ (37.6%): the highest
Table 3 Results of patients’ latent class analysis
Attribute Level Class 1: ‘stability focused’
(20.3%)a




Utility (SE) RI Utility (SE) RI Utility (SE) RI
Muscle damage 1 of 10,000 0.62 (0.09)b 21.9% 1.39 (0.07)b 49.7% 0.21 (0.04)b 25.6%
3 of 10,000 -0.62 (0.09)b -1.39 (0.07)b -0.21(0.04)b
Blood sampling twice No -0.28 (0.08)b 9.7% 0.005 (0.05) 0.2% -0.25 (0.03)b 30.5%
Yes 0.28 (0.08)b -0.005 (0.05) 0.25 (0.03)b
Curing pneumonia without hospitalization 95 of 100 0.14 (0.08) 4.9% 0.68 (0.06)b 24.3% 0.04 (0.04) 5.1%
90 of 100 -0.14 (0.08) -0.68 (0.06)b -0.04 (0.04)
Moderate muscle pain 5 of 100 0.13 (0.07) 4.6% 0.52 (0.05)b 18.7% 0.18 (0.04)b 22.1%
10 of 100 -0.13 (0.07) -0.52 (0.05)b -0.18 (0.04)b
Switch of cardiovascular drug No 1.68 (0.12)b 58.9% 0.20 (0.05)b 7.0% -0.13 (0.04)b 16.8%
Yes -1.68 (0.12)b -0.20 (0.05)b 0.13 (0.04)b
RI relative importance, SE standard error
a Average class probability
b p\ 0.05
Table 4 Results of pharmacists’ latent class analysis
Attribute Level Class 1: ‘risk focused’
(31.3%)a




Utility (SE) RI Utility (SE) RI Utility (SE) RI
Muscle damage 1 of 10,000 0.60 (0.06)b 40.6% 0.44 (0.10)b 11.7% 0.72 (0.08)b 20.0%
3 of 10,000 -0.60 (0.06)b -0.44 (0.10)b -0.72 (0.08)b
Blood sampling twice No -0.06 (0.06) 3.8% 0.45 (0.09)b 11.9% 1.39 (0.10)b 38.8%
Yes 0.06 (0.06) -0.45 (0.09)b -1.39 (0.10)b
Curing pneumonia without hospitalization 95 of 100 0.61 (0.06)b 41.4% 0.43 (0.09)b 11.3% 0.32 (0.07)b 8.8%
90 of 100 -0.61 (0.06)b -0.43 (0.09)b -0.32 (0.07)b
Moderate muscle pain 5 of 100 0.17 (0.06)b 11.6% 0.14 (0.09) 3.8% 0.26 (0.07)b 7.1%
10 of 100 -0.17 (0.06)b -0.14 (0.09) -0.26 (0.07)b
Switch of cardiovascular drug No 0.04 (0.06) 2.5% 2.31 (0.20)b 61.2% 0.90 (0.09)b 25.2%
Yes -0.04 (0.06) -2.31 (0.20)b -0.90 (0.09)b
RI relative importance, SE standard error
a Average class probability
b p\ 0.05
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importance was attached to avoidance of blood sampling
and to a lesser extent, like the previous class, to avoiding
changes in the current therapy. In contrast, in the patients’
third class (38.7%), blood sampling was unexpectedly
preferred over no blood sampling in otherwise identical
situations (‘certainty focused’).
Pharmacists in the ‘risk focused’ class were older and
more often male, whereas pharmacists in the ‘stability
focused’ class were younger and more often female. This
difference has parallels with the transition of pharmacy
practice in recent decades, towards a more patient-oriented
perspective. However, the number of pharmacists sponta-
neously reporting patient preferences as a reason for other
DDI management considerations was limited (n = 14
[7.9%]).
For patients, we found no clear association between
preference class and descriptive statistics, although an
association with educational level could not be excluded.
No relationship with health literacy was observed. About
one-quarter of patients who started the questionnaire did
not finish it; this included relatively more patients with
lower education. Patients with low health literacy or low
numeracy may have been underrepresented in our study
because of the complexity of assessing the DDI manage-
ment options. The mean SNS score on numeracy and the
mean overall FCCHL score on health literacy in this study
were in the same range as in the validation studies [27, 31].
Decision making about DDIs is complex, as it includes
several aspects: (1) a new or changing condition in which
treatment is assumed necessary, (2) a risk of the combi-
nation of both drugs, of which the exact magnitude is often
unknown, and (3) the potential management options of the
DDI, which may affect both the risk and the benefit of (1)
and (2) and that may also introduce new risks. We com-
bined the characteristics of these aspects in one conjoint
task, which enabled respondents to integrate the conse-
quences of the management options. The fact that the task
description focused primarily on managing the DDI may
have highlighted the risk originating from the DDI (serious
muscle problems). The presentation of data may have
influenced the respondents in several ways. First, serious
events with low risk were included as attribute. We used
descriptions with absolute risks and fixed denominators for
optimal understanding (e.g. 5 of 100 and 10 of 100 rather
than 5% and 10% or 1 of 20 vs. 1 of 10) [34–37]. Never-
theless, understanding (rare) risks and incorporating them
in healthcare decisions is difficult, especially for people
with lower health literacy and lower numeracy [25, 38, 39].
Second, risk perception is strongly influenced by contex-
tual factors, e.g. whether or not it is presented and per-
ceived as a dangerous problem [40–42]. Third, people are
sensitive to the framing of risks in terms of loss or gain.
People tend to respond more strongly to options described
as losses (e.g. a new serious adverse event) rather than as
gains (more effective cure of pneumonia) [34]. However,
this is also likely to happen in daily clinical practice.
In this context, it is interesting that the analysis showed
that all patients attached importance to the risk of serious
muscle problems, despite the low risk. Better chances of
curing pneumonia—a serious condition—were valued less.
However, this was not the case with pharmacists, who are
used to risk interpretation. When it comes to differences
between pharmacists and patients, the expressed prefer-
ences for the blood sampling attribute is notable. As
expected, pharmacists preferred a management option
solution without blood sampling, as there is no benefit in
the act of blood sampling itself as long as the levels of the
other attributes are identical. In fact, for one of the phar-
macist classes (‘practicality focused’), prevention of blood
sampling was the most important factor. In contrast, in the
‘certainty focused’ patient class, blood testing was pre-
ferred over no blood testing. It is conceivable that these
patients expected better control with blood tests, even
where all other shown attribute levels were identical. A
comparable effect has been observed with price, where
more expensive goods were incorrectly assumed to be of
better quality [43, 44]. Although the real value of the
expressed preference of blood sampling over no sampling
can be questioned, the results do suggest that most patients
in this study, who chronically use cardiovascular drugs, do
not experience blood sampling as very burdensome.
This study is not without limitations. First, we investi-
gated a fictitious DDI. Therefore, we cannot draw con-
clusions about preferences in any specific situation.
Patients may choose differently when they are confronted
with a DDI in daily practice, and pharmacists may choose
differently for specific patients. However, it is likely that
preferences will also vary in daily clinical practice.
Second, invitations were sent by email. Although inter-
net access is high in the Netherlands (in 2016: 94% of the
general population; 78% in the population aged[ 65 years
[45]), the oldest and frailest patients may well have been
underrepresented. Moreover, patients chronically using
cardiovascular drugs are often subject to DDIs, but they
need not to be representative for all patients facing DDIs.
Third, the subject of our CBC was complex. Respon-
dents not completely understanding the task may have
given irrational or random answers, and identifying irra-
tional answers is difficult [43, 44]. Some respondents may
have used simplifying heuristics, ranking attributes in
importance rather than making a trade-off [46]. However, it
is plausible that respondents deliberately valued some
attributes extremely high or low. Irrational answers may
have influenced the exact estimates but are unlikely to have
influenced the overall pattern. The preferred levels for all
classes were consistent with prior expectations for both risk
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and benefit attributes (preference for lower risk and higher
benefit).
Fourth, physicians were not included in the investiga-
tion. Although pharmacists are the healthcare providers
mostly involved in DDI management, consultation with the
prescriber or prescribers is an important part of the process.
The physician is an essential actor in decision making and
in effectuating DDI management options such as pre-
scription modifications and monitoring laboratory values.
Therefore, further investigations into DDI decision making
should include all three main stakeholders: patients, phar-
macists and physicians.
The observed variability in DDI management prefer-
ences can lead to incongruence between patients’ and
pharmacists’ assessments. Awareness of their own prefer-
ence and patients’ preferences can help healthcare provi-
ders in shared decision making. This can be stimulated by
incorporating the divergence of preferences in DDI man-
agement recommendations [47]. Further research is needed
to obtain insight into the DDI decision-making process and
to investigate the value and implementation of shared
decision making about DDIs in daily practice.
5 Conclusion
Our results show considerable variability in DDI manage-
ment preferences, among both patients and pharmacists.
Some attach the highest importance to clinical risks and
benefits, whereas others highly value practical implications
(such as the acceptance or rejection of blood testing). The
awareness of existing variability enables it to be incorpo-
rated into the development and application of DDI man-
agement recommendations: a step towards shared decision
making in this field.
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